Overall rank by patents
#28,123
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Amunix Pharmaceuticals, Inc.
USPTO PatentsView assignee record - 9 granted patents across 5 technology areas, active 2020–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
9
Total patents granted
5
CPC technology areas
20.2
Avg claims per patent
-
5-year filing velocity
The verdict
Amunix holds 9 US patents across 5 technology areas, rank #28,123 of 50,000 tracked assignees.
- #28,123
- of 50,000 US assignees by volume
- Top 45%
- by Innovation Score (36.9/100)
- 20.2
- avg claims per patent
Portfolio overview
Amunix Pharmaceuticals, Inc. has been granted 9 US utility patents between 2020 and 2025, placing Amunix Pharmaceuticals, Inc. at rank #28,123 across all assignees tracked by PlainPatent. This portfolio spans 5 distinct Cooperative Patent Classification (CPC) subclasses, averaging 20.2 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, Amunix Pharmaceuticals, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Amunix sits between Amirim Products Development & Patents Ltd. (9 patents, rank #28,119) and Aneumed, Inc. (9 patents, rank #28,127) - the closest US assignees by grant volume. The composite Innovation Score of 36.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2020 through 2025, with 9 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Amunix Pharmaceuticals, Inc.'s 20.2 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 5 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Amunix Pharmaceuticals, Inc. against peers pursuing similar technology classes.
Who files at Amunix's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Amirim Products D…
Amirim Products Development & Patents Ltd.
9 patents
- Amnio Technology
Amnio Technology LLC
9 patents
- Amplify Surgical
Amplify Surgical, Inc.
9 patents
- Amprion
Amprion, Inc.
9 patents
- Analog Value
Analog Value Ltd.
9 patents
- Analysis and Meas…
Analysis and Measurement Services Corp.
9 patents
- Analytical Graphi…
Analytical Graphics Inc.
9 patents
- Aneumed
AneuMed, Inc.
9 patents
- Amunix Pharmaceut… ◀
Amunix Pharmaceuticals, Inc.
9 patents
What this shows Amunix holds 9 patents at rank #28,123, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Amunix
By rank, the assignees closest to #28,123 in granted patent volume.
- Amirim Products Development & Patents Ltd. #28,119 · 9 patents
- Amnio Technology Llc #28,120 · 9 patents
- Amplify Surgical, Inc. #28,121 · 9 patents
- Amprion, Inc. #28,122 · 9 patents
- Analog Value Ltd. #28,124 · 9 patents
- Analysis And Measurement Services Corp. #28,125 · 9 patents
- Analytical Graphics Inc. #28,126 · 9 patents
- Aneumed, Inc. #28,127 · 9 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Amunix's primary technology class.
- The Regents Of The University Of California 1,387 in class
- Novartis Ag 1,071 in class
- Merck Sharp & Dohme Llc 889 in class
- Bristol-myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board Of Regents Of The University Of Texas System 744 in class
- Hoffmann-la Roche Inc. 722 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 721 in class
Amunix's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
37 Top 45% higher than 55% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2020 | 1 | 11.1% |
| 2021 | 2 | 22.2% |
| 2023 | 1 | 11.1% |
| 2024 | 3 | 33.3% |
| 2025 | 2 | 22.2% |
Which technologies does Amunix Pharmaceuticals, Inc. patent most?
Top 5 of 5 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Complex
Frequently Asked Questions
How many patents does Amunix Pharmaceuticals, Inc. hold?
Amunix Pharmaceuticals, Inc. holds 9 US granted patents filed between 2020 and 2025, spanning 5 technology areas.
What is Amunix Pharmaceuticals, Inc.'s Innovation Score?
Amunix Pharmaceuticals, Inc. has an Innovation Score of 36.9 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Amunix Pharmaceuticals, Inc. focus on?
Amunix Pharmaceuticals, Inc.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 9 patents. The company has filed patents in 5 CPC subclasses total.
Is Amunix Pharmaceuticals, Inc.'s patent filing rate increasing or decreasing?
Insufficient historical data is available to calculate a velocity trend for Amunix Pharmaceuticals, Inc..
What does claim depth mean for Amunix Pharmaceuticals, Inc.'s patents?
Amunix Pharmaceuticals, Inc.'s patents average 20.2 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Amunix Pharmaceuticals, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Amunix's 9 grants land it in the top 45% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Amunix ranks #28,123 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.